GSK 6K Director/pdmr Shareholding

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Vesting of Performance Share Plan Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2022 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards were made in 2022 and the three-year performance period commenced on 1 January 2022 and ended on 31 December 2024. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.

The performance measure vesting details for those PDMRs who received awards in 2022 are set out in the following table.

		Outcome and Vesting Level
Portion of the Award	Measure and Outcome	% of maximum	% of award
30%	Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 5th, against a comparator group of 10 global pharmaceutical companies including GSK.	40%	12%
20%	Total Sales - For the three-year period, the Company achieved sales across our marketed products for the measure of £86.15bn, which is above the level of £80.29bn required for 100% vesting. The threshold vesting level was £75.71bn.	100%	20%
20%	Total Profit - For the three-year period, the Company achieved £24.2bn, which is above the level of £23.62bn required for 100% vesting. The threshold vesting level was £22.27bn.	100%	20%
20%	Pipeline Progress - measure is equally weighted between: - Pivotal trial starts - Major regulatory approvals	100% 87.5%	10% 8.75%
10%	Trust: Environment - For the three-year period, all criteria for achieving our Trust priority and goal of having a Nature Net Positive and Climate Net Zero impact by 2030 have been met or exceeded in advance of the target date required to result in maximum vesting for this measure.	100%	10%
	Total vesting for 2022 award Lapsed	80.75 19.25	80.75%

The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 18 February 2025. The balance of the award made to each PDMR and PCA has lapsed.

The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting date were £14.43 and $36.61.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan. These shares are now subject to a two-year hold.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	420,177

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	88,027

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	47,121

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	143,381

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	67,390

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	50,221

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	23,604

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	208,808

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	14,763

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The number of ADSs vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	47,681

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$36.6355	25,705

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	153,657

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	72,219

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	135,261

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	63,573

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	70,869

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	33,309

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	133,405

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	62,701

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	97,444

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	45,799

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	10,755

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2022 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.2531	5,055

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-18
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: February 20, 2025

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

GSK (GSK) 6-KDirector/pdmr Shareholding